Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Zhejiang CONBA Pharmaceutical Co.,Ltd. (600572.SS)
CNY4.36
+0.11 (+2.59%)
CN SHH Healthcare Drug Manufacturers - General
Address
No. 568, Binkang Road
Hangzhou, CN
Hangzhou, CN
CEO
Guoliang Luo
Website
conbagroup.com
IPO
2004-04-12
ISIN CNE000001H86
Description
Zhejiang CONBA Pharmaceutical Co., Ltd., a subsidiary of Zhejiang Traditional Chinese Medicine Health Industry Group Co., Ltd., is headquartered in Hangzhou, China. Established in 1969, and formerly known as Lanxi Yunshan Pharmaceutical Factory until its name change in October 1999, the company specializes in the research, development, manufacturing, and distribution of traditional Chinese medicines and botanical products across China. Its broad portfolio extends to include chemical pharmaceuticals, proprietary Chinese medicines, vision care products, dietary supplements, general health supplies, everyday wellness goods, food items, and various personal care products.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY4.36
+0.11 (+2.59%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
54M
Beta
0.23
Float Shares
1.60B
Free Float %
63.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.68% | +1.68% | -5.58% | -5.58% | -8.44% | -5.16% | -7.03% | -38.87% | -7.84% | -31.88% | +249.59% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
4.36
DCF (Unlevered)
12.45
+185.7%
DCF (Levered)
13.73
+214.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
3.90
Safe zone
Piotroski F-Score
8 / 9
Strong
MOAT Score
6 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
3 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - General: +6.6%-0.6% Q1'26: +13.1% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%-24.0% Q1'26: +21.9% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+12.7% ★ Q1'26: +10.9% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+10.1% Q1'26: +13.2% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%+8.3% Q1'26: +11.9% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%+0.3% Q1'26: -14.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×0.51× ★ Q1'26: 0.34× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
5.30B
est: 5.89B (-10.0%)
|
6.02B
est: 6.85B (-12.1%)
|
5.29B
est: 7.66B (-30.9%)
|
7.02B
est: 5.89B (+19.2%)
|
6.77B
est: 6.85B (-1.2%)
|
5.91B
est: 7.66B (-22.9%)
|
6.57B
est: 8.47B (-22.4%)
|
6.00B
est: 6.03B (-0.5%)
|
6.73B
est: 6.73B (+0.0%)
|
6.52B
est: 7.22B (-9.7%)
|
6.47B
est: 8.06B (-19.7%)
|
7.22B
7.22B – 7.22B
-10.4% YoY
|
7.97B
7.97B – 7.97B
+10.4% YoY
|
8.75B
8.75B – 8.75B
+9.8% YoY
|
| EBITDA |
1.06B
est: 892.22M (+18.5%)
|
909.81M
est: 1.04B (-12.4%)
|
1.21B
est: 1.16B (+4.2%)
|
1.33B
est: 892.22M (+49.0%)
|
1.18B
est: 1.04B (+13.5%)
|
847.64M
est: 1.16B (-27.0%)
|
956.65M
est: 1.28B (-25.4%)
|
963.34M
est: 914.03M (+5.4%)
|
1.13B
est: 1.02B (+10.7%)
|
913.75M
est: 1.11B (-17.6%)
|
997.71M
est: 1.24B (-19.4%)
|
1.11B
1.11B – 1.11B
-10.4% YoY
|
1.22B
1.22B – 1.22B
+10.4% YoY
|
1.34B
1.34B – 1.34B
+9.8% YoY
|
| EBIT |
883.27M
est: 617.87M (+43.0%)
|
679.38M
est: 718.91M (-5.5%)
|
992.64M
est: 804.10M (+23.4%)
|
1.09B
est: 617.87M (+76.2%)
|
917.23M
est: 718.91M (+27.6%)
|
581.56M
est: 804.10M (-27.7%)
|
674.18M
est: 888.46M (-24.1%)
|
690.41M
est: 632.98M (+9.1%)
|
804.32M
est: 706.32M (+13.9%)
|
579.93M
est: 760.95M (-23.8%)
|
652.96M
est: 849.49M (-23.1%)
|
760.92M
760.92M – 760.92M
-10.4% YoY
|
839.79M
839.79M – 839.79M
+10.4% YoY
|
921.94M
921.94M – 921.94M
+9.8% YoY
|
| Net Income |
440.37M
est: 813.30M (-45.9%)
|
441.07M
est: 672.21M (-34.4%)
|
711.12M
est: 746.90M (-4.8%)
|
815.16M
est: 813.30M (+0.2%)
|
-345.63M
est: 672.21M (-151.4%)
|
453.30M
est: 746.90M (-39.3%)
|
2.02B
est: 821.59M (+145.6%)
|
358.12M
est: 348.55M (+2.7%)
|
591.57M
est: 647.31M (-8.6%)
|
622.42M
est: 687.02M (-9.4%)
|
474.36M
est: 773.96M (-38.7%)
|
574.23M
574.23M – 574.23M
-25.8% YoY
|
699.06M
699.06M – 699.06M
+21.7% YoY
|
823.89M
823.89M – 823.89M
+17.9% YoY
|
| SGA |
1.86B
est: 2.57B (-27.6%)
|
2.04B
est: 2.99B (-31.9%)
|
2.64B
est: 3.35B (-21.2%)
|
3.94B
est: 2.57B (+53.2%)
|
3.84B
est: 2.99B (+28.2%)
|
2.97B
est: 3.35B (-11.4%)
|
2.96B
est: 3.70B (-19.9%)
|
2.58B
est: 2.64B (-2.1%)
|
2.83B
est: 2.94B (-3.7%)
|
2.48B
est: 2.77B (-10.6%)
|
1.55B
est: 3.10B (-50.1%)
|
2.77B
2.77B – 2.77B
-10.4% YoY
|
3.06B
3.06B – 3.06B
+10.4% YoY
|
3.36B
3.36B – 3.36B
+9.8% YoY
|
| EPS |
0.19
est: 0.33 (-41.8%)
|
0.18
est: 0.27 (-33.3%)
|
0.28
est: 0.30 (-6.7%)
|
0.31
est: 0.33 (-5.1%)
|
-0.13
est: 0.27 (-148.1%)
|
0.18
est: 0.30 (-40.0%)
|
0.79
est: 0.33 (+137.9%)
|
0.14
est: 0.14 (-0.5%)
|
0.23
est: 0.26 (-11.5%)
|
0.25
est: 0.28 (-10.7%)
|
0.19
est: 0.31 (-38.7%)
|
0.23
0.23 – 0.23
-25.8% YoY
|
0.28
0.28 – 0.28
+21.7% YoY
|
0.33
0.33 – 0.33
+17.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-25 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-15 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
1.03B
OE per share TTM
0.39
Owner's Yield
9.58%
Maintenance CapEx ratio
45.98%
Maint CapEx / Avg PPE
47.2%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 22 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 290.7K | 0.39% |
| 2 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 43.1K | 0.46% |
| 3 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 11.0K | 0.44% |
| 4 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L | 0.00% | 72.9K | 0.17% |
| 5 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Accumulating VFEA.L | 0.00% | 72.9K | 0.17% |
| 6 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 103.2K | 0.29% |
| 7 | Vanguard International High Dividend Yield ETF VYMI | 0.00% | 200.6K | 0.07% |
| 8 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 11.8K | 0.48% |
| 9 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 26.7K | 0.26% |
| 10 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.32M | 0.06% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
77.6K
Shares Outstanding
2.54B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chunling Xu | Vice President | — | female |
| Guoliang Luo | President & Director | — | male |
| Jianfeng Ye | Vice President & Director | — | male |
| Ming Chen | Vice President, Chief Financial Officer & Director | — | male |
| Zucheng Jin | Vice President & Board Secretary | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600572.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
